Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension
- 1 March 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 201 (5), 575-585
- https://doi.org/10.1164/rccm.201906-1141oc
Abstract
Objectives: Recently, rare heterozygous mutations in GDF2 were identified in patients with pulmonary arterial hypertension (PAH). GDF2 encodes the circulating bone morphogenetic protein, BMP9, which is a ligand for the BMP type 2 receptor (BMPR2). Here we determine the functional impact of GDF2 mutations and characterised plasma BMP9 and BMP10 levels in patients with idiopathic PAH. Methods: Missense BMP9 mutant proteins were expressed in vitro and the impact on BMP9 protein processing and secretion, endothelial signalling and functional activity was assessed. Plasma BMP9 and BMP10 levels and activity were assayed in PAH patients with GDF2 mutations, and controls. Levels were also measured in a larger cohort of controls (n=120) and idiopathic PAH patients (n=260). Main Results: We identified novel rare variation at the GDF2 and BMP10 loci, including copy number variation. In vitro, BMP9 missense proteins demonstrated impaired cellular processing and secretion. PAH patients carrying these mutations exhibited reduced plasma levels of BMP9 and reduced BMP activity. Unexpectedly, plasma BMP10 levels were also markedly reduced in these individuals. Although overall BMP9 and BMP10 levels did not differ between PAH patients and controls, BMP10 levels were lower in PAH females. A subset of PAH patients had markedly reduced plasma levels of BMP9 and BMP10 in the absence of GDF2 mutations. Conclusions: Our findings demonstrate that GDF2 mutations result in BMP9 loss-of-function and are likely causal. These mutations lead to reduced circulating levels of both BMP9 and BMP10. These findings support therapeutic strategies to enhance BMP9 or BMP10 signalling in PAH.Keywords
This publication has 29 references indexed in Scilit:
- Relevant Issues in the Pathology and Pathobiology of Pulmonary HypertensionJournal of the American College of Cardiology, 2013
- Genetics and Genomics of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2013
- BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic TelangiectasiaAmerican Journal of Human Genetics, 2013
- A Novel Channelopathy in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial HypertensionCirculation: Cardiovascular Genetics, 2012
- BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomainCellular and Molecular Life Sciences, 2011
- Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence FactorCirculation Research, 2008
- Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cellsBlood, 2006
- Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2004
- Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic TelangiectasiaThe New England Journal of Medicine, 2001